GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and to Evaluate the Interaction Between GSK3915393 and Grapefruit Juice and Itraconazole
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 65
- Registration Number
- NCT04604795
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India
- Conditions
- Interventions
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 310
- Registration Number
- NCT04600752
- Locations
- 🇮🇳
GSK Investigational Site, Purne, India
Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 56
- Registration Number
- NCT04585009
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 243
- Registration Number
- NCT04581824
- Locations
- 🇨🇳
GSK Investigational Site, Taipei, Taiwan
A Study to Assess the Local Cutaneous and Ocular Tolerance of Three Developmental Facial Skin-care Formulations.
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 150
- Registration Number
- NCT04557371
- Locations
- 🇩🇪
GSK Investigational Site, Schenefeld, Schleswig-Holstein, Germany
Mepolizumab Long-term Study to Assess Real World Safety and Effectiveness of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Japan
- Conditions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 120
- Registration Number
- NCT04551989
- Locations
- 🇯🇵
GSK Investigational Site, Yamaguchi, Japan
Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT04549363
- Locations
- 🇺🇸
GSK Investigational Site, Chapel Hill, North Carolina, United States
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 141
- Registration Number
- NCT04544995
- Locations
- 🇬🇧
GSK Investigational Site, Sutton, United Kingdom
A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT04544956
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers
- Conditions
- Interventions
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 500
- Registration Number
- NCT04535037
- Locations
- 🇪🇸
GSK Investigational Site, Sevilla, Spain